Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model

   
Lizunov A.V.1 , Okunevich I.V.2, Lebedev A.A.2, Bychkov E.R.3, Piotrovskiy L.B.2, Shabanov P.D.3

1. Institute of Experimental Medicine, St. Petersburg, Russia; St Petersburg University, St. Petersburg, Russia
2. Institute of Experimental Medicine, St. Petersburg, Russia
3. Institute of Experimental Medicine, St. Petersburg, Russia; Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, St. Petersburg, Russia
Section: Experimental Study
DOI: 10.18097/PBMC20206604326      PubMed Id: 32893822
Year: 2020  Volume: 66  Issue: 4  Pages: 326-331
The tested drug cramizol exhibits lipid-lowering and anti-atherogenic effects. Cramizol reduces blood cholesterol and triglycerides. It also increases HDL and reduces the atherogenic index in rats with the chronic dyslipidemia model induced by a hypercholesterol diet. Cramizol is effective as a hypolipidemic agent and its efficiency is comparable with the reference drug, phenofibrate. Cramizol increases expression of the ApoA1 and ApoC2 genes, and also reduces expression of the Scarb1 gene in rats with experimentally induced hyperlipidemia. These mechanisms could be the basis of its hypolipidemic and anti-atherogenic actions.
Download PDF:
Keywords: cramizol, experimental chronic dyslipidemia, cholesterol, alimentary model, triglycerides, apolipoprotein A1, apolipoprotein C2, SR-B1
Citation:

Lizunov, A. V., Okunevich, I. V., Lebedev, A. A., Bychkov, E. R., Piotrovskiy, L. B., Shabanov, P. D. (2020). Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model. Biomeditsinskaya khimiya, 66(4), 326-331.
References  
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)